Mt 25 005 ci

MEFs and mouse breast tumor lines: DMEM (Corning mt10013cv) supplemented with 10% FBS (Atlanta Biologicals), 1% pen/strep (Fisher 30002ci) and 2mM L-glutamine (total 6mM) (Fisher MT25005CI). MDA-MB468, MDA-MB 231, Myc-CaP (2015), and U87: DMEM supplemented with 10% FBS and 1% pen/strep. HCC1419, HCC1187, HCC 1937, HCC 1806, BT549, ZR75-1, PC3, LNCAP, DBTRG: RPMI (Fisher 10040cv) supplemented with 10% FBS and 1% pen/strep. CaP8 cells (2015): DMEM with 10% FBS, 1% pen/strep, and 5ug/mL insulin (Sigma I9278). Neurospheres: stem cell media with 10ug/mL FGF (R&D Systems 233-FB-025), 20ug/mL EGF (Peprotech AF-100-15) and heparin (from Dr. Raymund Yong, May 2015). All cells were cultured in a 37°C incubator with humidity and 5% CO₂. Cell lines were obtained from ATCC (which authenticate cell lines using several methods including DNA fingerprinting) in 2006, with the exception of MEFs, MCCL-278, and MCCL-357 which were produced in our lab from mice (2012-2016). Cell lines were clear of mycoplasma as determined by the Lonza kit (LT07-418) within 6 months of their use. Cell lines were further authenticated in 2015 by LabCorp using a short tandem repeat method.